SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors rally behind optimistic sentiment regarding global expansion and potential upcoming oncology breakthroughs, while social media buzz focuses on a significant short interest and frustration with regulatory scrutiny. The community is actively discussing rumors of imminent international deals and the potential for a major short squeeze.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing explosive investor interest and a significant price gap following a strong earnings report that highlighted accelerating AI infrastructure demand and robust data center growth. The community is actively debating the stock's valuation, with many bullish investors cheering the company's competitive position while others express caution over the rapid, parabolic run-up and broader sector volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is facing significant community frustration and selling pressure as investors rotate capital into other semiconductor stocks, despite the company's dominant AI market position. Traders are actively debating whether this stagnation is a result of market manipulation or a lack of near-term catalysts leading into the upcoming earnings report.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is trending following the announcement of a landmark 10-year colocation agreement with Cerebras Systems for an AI data center, with the community actively debating whether the company's valuation gap will close as infrastructure demand scales. Investors are heavily focused on the stock's potential for a long-term re-rating alongside the upcoming Cerebras IPO, while managing concerns over high short interest and potential share dilution.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging amid a broad rally in the semiconductor sector, fueled by intense investor demand for memory chips essential to AI infrastructure and data center growth. The community remains highly bullish, citing strong fundamentals, significant capacity constraints, and anticipation of a continued re-rating as the company expands its role in the AI supply chain.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as investors react to its potential as a quantum-resistant privacy asset, with the community closely tracking its performance relative to broader market shifts and anticipated regulatory developments. While some traders are aggressively building positions in anticipation of a privacy sector rotation, others remain cautious of the volatility and debating the long-term outlook for the coin versus Bitcoin.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after delivering strong earnings and an improved margin outlook that overshadowed a revenue miss, fueling intense community discussion about a potential short squeeze. Investors are actively debating whether this performance marks a sustainable re-rating for the undervalued stock or if lingering concerns regarding the company's accounting reputation and ongoing legal developments will cap the momentum.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart shares are seeing increased volatility and active community discussion following the announcement of a multi-year loan purchase agreement with Fortress Investment Group. Investors are debating the stock's high short interest and technical chart patterns, with many focusing on whether this partnership and recent sentiment shifts in the fintech sector can spark a sustained rally toward previous price levels.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing an explosive, parabolic rally driven by structural memory chip shortages and massive demand from AI data centers that analysts expect to persist for several years. The stock's rapid appreciation has sparked intense debate among the community, with many traders riding the momentum toward new highs while others express skepticism over the sustainability of such aggressive vertical moves.

Roundhill ETF Trust - Roundhill Memory ETF

The DRAM ETF is surging as investors target a memory supercycle fueled by an explosive, AI-driven demand for HBM and NAND flash storage that exceeds current supply. The community is heavily focused on this 'digital oil' narrative, viewing the ETF as a strategic way to capture exposure to key memory industry leaders like Micron, Samsung, and SK Hynix.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Cadrenal is now planning a randomized, placebo-controlled study alongside standard anticoagulants.</li><li>The company's Phase 2 data showed over a 25% reduction in clotting, though the trial missed its primary endpoint on platelet recovery.</li><li>Cadrenal is also advancing its 12-LOX platform into areas like obesity and diabetes.</li></ul>Shares of Cadrenal Therapeutics, Inc. (CVKD) saw its retail sentiment peak to a record high late Sunday after the U.S. Food and Drug Administration (FDA) cleared the path for its blood clot drug CAD-1005 to advance into a Phase 3 trial for heparin-induced thrombocytopenia (HIT).<a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> jumped nearly 3% overnight heading into Monday. On Friday, shares fell 2% and extended losses by another 2% in extended trading.&nbsp;<h2 class="st-heading-2">CVKD Eyes Phase 3 After FDA Feedback</h2>The company said that the guidance came after its End-of-Phase 2 meeting, which was completed in March, covered protocol design, study population, dosing, background therapy, safety database, and the primary endpoint of new or worsening thrombotic events. Based on the feedback, Cadrenal will initiate a randomized, blinded, placebo-controlled Phase 3 trial evaluating CAD-1005 alongside standard anticoagulant therapy.“Building on our Phase 2 experience with CAD-1005 in HIT and now with FDA guidance for Phase 3, Cadrenal is positioned to pursue a pivotal trial for the first new therapy for HIT in more than two decades,” CEO Quang X. Pham said in a statement.&nbsp;&nbsp;In February, Cadrenal reported results from the trial, which showed over a 25% absolute reduction in thrombotic events in patients treated with CAD-1005 on top of standard anticoagulants, compared with placebo. The study did not meet its primary endpoint based on platelet count recovery, which the company said may not be an appropriate indicator for clinical benefit in HIT.Despite similar platelet recovery rates across both groups, fewer thrombotic events were observed in the CAD-1005 arm, with high event rates continuing in the placebo group. The company had earlier scheduled the End-of-Phase 2 meeting with the FDA in February and subsequently completed it in March, where it clarified a potential registrational pathway and began incorporating regulatory feedback into its Phase 3 protocol.<h2 class="st-heading-2">Cadrenal Targets 2029 NDA with Phase 3 Study</h2>Cadrenal’s Phase 3 study is expected to enroll around 120 patients across up to 50 clinical centers globally. Patients with suspected HIT will be randomized to receive CAD-1005 or placebo while continuing standard anticoagulant therapy and treated for up to 14 days during hospitalization.&nbsp;The primary endpoint will assess to see how often patients develop new blood clots, or if existing clots get worse, among those who are confirmed to have HIT, using a lab test called the Serotonin Release Assay, with at least one interim analysis planned. The company said the study is aimed at a potential New Drug Application submission in 2029.Cadrenal Expands Drug PipelineIn March, Cadrenal said it was expanding its pipeline of drugs that target the 12-lipoxygenase (12-LOX) pathway after adding more compounds to its portfolio, including some that can be taken orally. However, the company made clear that its focus remains on advancing CAD-1005 for HIT.However, the company said that early research suggests that blocking the 12-LOX pathway could have potential uses beyond HIT, including in conditions like obesity, type 2 diabetes and other inflammatory diseases. CAD-1005 is currently the only 12-LOX inhibitor currently in clinical-stage development and has received Orphan Drug and Fast Track designations from the FDA, along with orphan drug status from the European Medicines Agency.<h2 class="st-heading-2">How Do Retail Traders Feel About CVKD?</h2>On Stocktwits, retail sentiment for CVKD was ‘extremely bullish’ at a record high of 99/100 amid ‘extremely high’ message volume.CVKD stock has declined 62% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gme-stock-ebay-deal-etsy-alternative-retail-traders/cZQAAUBRe7W">GameStop–eBay Deal Buzz Sparks Retail Backlash, With Some Floating Etsy Instead&nbsp;</a>

 In this photo illustration, the Cadrenal Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug 

Its late-stage trial targets 120 patients globally, with results aimed at pushing for a potential NDA filing in 2029.

Equity

<ul class="summary-bullets"><li>The company outlined progress on its anticoagulation pipeline, including its HIT program VLX-1005, at a Lytham Partners investor summit.</li><li>Cadrenal said VLX-1005 has completed a Phase 2 trial, with data under review and FDA discussions planned.</li><li>Shares fell 4% on Friday before ticking higher after the close.</li></ul>Cadrenal Therapeutics drew renewed retail investor interest on Tuesday after&nbsp;the biotech company&nbsp;outlined progress across its anticoagulation pipeline, VLX-1005,&nbsp; which it&nbsp;acquired from Veralox Therapeutics in December.At a&nbsp;fireside chat at the Lytham Partners Healthcare Investor Summit,&nbsp;Cadrenal CEO Quang Pham and acting Chief Scientific Officer Matt Boxer described how the asset fits into the company’s broader strategy to address gaps left by long-standing anticoagulants such as Warfarin and Heparin, as well as newer direct oral anticoagulants (DOACs).The stock fell 4% to close at $7.87 on Friday, before edging up 0.8% in after-hours trading.<h2 class="st-heading-2">Targeting A High-Risk Complication Of Heparin Use</h2>VLX-1005 is being developed for heparin-induced thrombocytopenia, or HIT, a condition caused by an immune reaction to heparin. Boxer said patients exposed to heparin can develop antibodies that form complexes with platelet factor 4.This process leads to platelet consumption while simultaneously triggering clot formation, he said. As a result, patients can develop thrombosis and ischemia, with cases sometimes progressing to amputations, organ failure, and death, even though they were initially given heparin for anticoagulation.Boxer said existing treatments mainly work by inhibiting the clotting cascade, a strategy that can increase bleeding risk in patients with already low platelet counts. He added that about 50,000 confirmed new HIT cases occur each year in the U.S., driven in part by the continued use of heparin in cardiovascular surgery, with cases also seen globally.<h2 class="st-heading-2">Phase 2 Data And Next Steps</h2>VLX-1005 was designed to act earlier in the disease process by blocking 12-lipoxygenase (12-LOX), an enzyme that plays a role in triggering immune-driven platelet activation.&nbsp;The program has completed a Phase 2 clinical trial, with the database locked and data currently under analysis. Pham said the company has been engaging with primary investigators through introductions made by the Veralox team and expects the data to be published in the near term.VLX-1005 has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). Pham said work on chemistry, manufacturing and controls is underway, with discussions with the FDA expected later this quarter.<h2 class="st-heading-2">Other Programs In Development</h2>Alongside VLX-1005, Cadrenal is advancing Tecarfarin, a vitamin K antagonist designed to be more kidney-friendly, for patients with end-stage kidney disease and atrial fibrillation, as well as those with implanted mechanical heart valves and left ventricular assist devices. Tecarfarin holds orphan drug designations for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), as well as for those with left ventricular assist devices (LVADs).Pham also referenced Fruinexian, a short-acting Factor XI candidate acquired in late 2025 for use in cardiovascular surgery, noting broader industry interest in Factor XI inhibitors as the company awaits the first approvals in the class.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Cadrenal was ‘neutral’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cvkd_ss_png_379707bd48.webp" alt="cvkd ss.png" width="969" height="140"><figcaption>CVKD sentiment and message volume as of January 19 | Source: Stocktwits</figcaption></figure>One user said, “<a href="https://stocktwits.com/symbol/CVKD">$CVKD</a> is showing early strength.”<stembedurl>https://stocktwits.com/JoannMotta/message/642239634</stembedurl>&nbsp;Another user described the stock’s current levels as a zone to keep&nbsp;an eye on.<stembedurl>https://stocktwits.com/LydiaBoyce/message/642238255</stembedurl><a href="https://stocktwits.com/symbol/CVKD">Cadrenal’s stock</a> has declined 57% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest CVKD News

CVKDCadrenal Therapeutics, Inc.